Search research articles
Contact Us
Filters
Showing results (61-70 of 129) with videos related to
Page
of 13
Sort By:
Advances in Therapy
|
April 16, 2022
Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart<sup>®</sup> Injector: Results of the Prospective Cohort Study REBIFLECT
Peter Rieckmann, Tjalf Ziemssen, Iris-Katarina Penner, et al.
Case Reports in Neurology
|
October 30, 2023
Can Growth Hormone Lead to a Faster Recovery from Guillain-Barré Syndrome? Case Report of the First Therapeutic Use in One Patient
Felix Amereller, Jochen Schopohl, Sylvère Störmann, et al.
FEMS Immunology and Medical Microbiology
|
March 22, 2003
Production of IL-12 and IL-18 in human dendritic cells upon infection by Listeria monocytogenes
Annette Kolb-Mäurer, Ulrike Kämmerer, Mathias Mäurer, et al.
Advances in Therapy
|
August 9, 2021
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
Gavin Giovannoni, Giancarlo Comi, Kottil Rammohan, et al.
Therapeutic Advances in Neurological Disorders
|
January 26, 2012
Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis
Peter Rieckmann, Fedor Heidenreich, Michael Sailer, et al.
Multiple Sclerosis and Related Disorders
|
February 19, 2018
The use of satellite data to measure ultraviolet-B penetrance and its potential association with age of multiple sclerosis onset
Ofer Amram, Nadine Schuurman, Ellen Randall, et al.
Clinical Therapeutics
|
March 9, 2019
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis
Patrick Vermersch, Vittorio Martinelli, Claudia Pfleger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 5, 2002
Evidence for shoulder girdle dystonia in selected patients with cervical disc prolapse
Georg Becker, Daniela Berg, Niels Kruse, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 10, 2016
Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study
Omar Khan, Peter Rieckmann, Alexey Boyko, et al.
BMC Cancer
|
October 20, 2006
Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26)
Dirk Vordermark, Klemens Ruprecht, Peter Rieckmann, et al.
Page
of 13
Search research articles
Search
Showing results (61-70 of 129) with videos related to
Sort By:
Page
of 13
Advances in Therapy
|
April 16, 2022
Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart<sup>®</sup> Injector: Results of the Prospective Cohort Study REBIFLECT
Peter Rieckmann, Tjalf Ziemssen, Iris-Katarina Penner, et al.
Case Reports in Neurology
|
October 30, 2023
Can Growth Hormone Lead to a Faster Recovery from Guillain-Barré Syndrome? Case Report of the First Therapeutic Use in One Patient
Felix Amereller, Jochen Schopohl, Sylvère Störmann, et al.
FEMS Immunology and Medical Microbiology
|
March 22, 2003
Production of IL-12 and IL-18 in human dendritic cells upon infection by Listeria monocytogenes
Annette Kolb-Mäurer, Ulrike Kämmerer, Mathias Mäurer, et al.
Advances in Therapy
|
August 9, 2021
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
Gavin Giovannoni, Giancarlo Comi, Kottil Rammohan, et al.
Therapeutic Advances in Neurological Disorders
|
January 26, 2012
Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis
Peter Rieckmann, Fedor Heidenreich, Michael Sailer, et al.
Multiple Sclerosis and Related Disorders
|
February 19, 2018
The use of satellite data to measure ultraviolet-B penetrance and its potential association with age of multiple sclerosis onset
Ofer Amram, Nadine Schuurman, Ellen Randall, et al.
Clinical Therapeutics
|
March 9, 2019
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis
Patrick Vermersch, Vittorio Martinelli, Claudia Pfleger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 5, 2002
Evidence for shoulder girdle dystonia in selected patients with cervical disc prolapse
Georg Becker, Daniela Berg, Niels Kruse, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 10, 2016
Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study
Omar Khan, Peter Rieckmann, Alexey Boyko, et al.
BMC Cancer
|
October 20, 2006
Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26)
Dirk Vordermark, Klemens Ruprecht, Peter Rieckmann, et al.
Page
of 13